The PRESIDE (PhaRmacogEnomicS In DEpression) Trial: a double-blind randomised controlled trial of pharmacogenomic-informed prescribing of antidepressants on depression outcomes in patients with major depressive disorder in primary care.
Antidepressants
General practice
Major depressive disorder
Mental health
Pharmacogenomics
Primary care
Randomised controlled trial
Journal
Trials
ISSN: 1745-6215
Titre abrégé: Trials
Pays: England
ID NLM: 101263253
Informations de publication
Date de publication:
19 May 2023
19 May 2023
Historique:
received:
01
05
2023
accepted:
06
05
2023
medline:
22
5
2023
pubmed:
20
5
2023
entrez:
19
5
2023
Statut:
epublish
Résumé
The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs. The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18-65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention. This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care. Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.
Sections du résumé
BACKGROUND
BACKGROUND
The evidence for the clinical utility of pharmacogenomic (PGx) testing is growing, and guidelines exist for the use of PGx testing to inform prescribing of 13 antidepressants. Although previous randomised controlled trials of PGx testing for antidepressant prescribing have shown an association with remission of depression in clinical psychiatric settings, few trials have focused on the primary care setting, where most antidepressant prescribing occurs.
METHODS
METHODS
The PRESIDE Trial is a stratified double-blinded randomised controlled superiority trial that aims to evaluate the impact of a PGx-informed antidepressant prescribing report (compared with standard prescribing using the Australian Therapeutic Guidelines) on depressive symptoms after 12 weeks, when delivered in primary care. Six hundred seventy-two patients aged 18-65 years of general practitioners (GPs) in Victoria with moderate to severe depressive symptoms, measured using the Patient Health Questionnaire-9 (PHQ-9), will be randomly allocated 1:1 to each arm using a computer-generated sequence. Participants and GPs will be blinded to the study arm. The primary outcome is a difference between arms in the change of depressive symptoms, measured using the PHQ-9 after 12 weeks. Secondary outcomes include a difference between the arms in change in PHQ-9 score at 4, 8 and 26 weeks, proportion in remission at 12 weeks, a change in side effect profile of antidepressant medications, adherence to antidepressant medications, change in quality of life and cost-effectiveness of the intervention.
DISCUSSION
CONCLUSIONS
This trial will provide evidence as to whether PGx-informed antidepressant prescribing is clinically efficacious and cost-effective. It will inform national and international policy and guidelines about the use of PGx to select antidepressants for people with moderate to severe depressive symptoms presenting in primary care.
TRIAL REGISTRATION
BACKGROUND
Australian and New Zealand Clinical Trial Registry ACTRN12621000181808. Registered on 22 February 2021.
Identifiants
pubmed: 37208772
doi: 10.1186/s13063-023-07361-6
pii: 10.1186/s13063-023-07361-6
pmc: PMC10197047
doi:
Substances chimiques
Selective Serotonin Reuptake Inhibitors
0
Antidepressive Agents
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
342Subventions
Organisme : MRFF
ID : MRF1200060
Informations de copyright
© 2023. The Author(s).
Références
Clin Pharmacol Ther. 2017 Jul;102(1):37-44
pubmed: 27997040
Clin Pharmacol Ther. 2023 Apr 9;:
pubmed: 37032427
Clin Pharmacol Ther. 2011 May;89(5):662-73
pubmed: 21412232
Br J Clin Pharmacol. 2020 Jul;86(7):1281-1288
pubmed: 31823381
Front Pharmacol. 2021 Mar 18;12:636650
pubmed: 33815120
Clin Pharmacol Ther. 2022 Dec;112(6):1303-1317
pubmed: 36111494
Drugs Context. 2015 Oct 08;4:212290
pubmed: 26576188
Lancet. 2021 Nov 6;398(10312):1700-1712
pubmed: 34634250
Aust J Gen Pract. 2019 Mar;48(3):100-105
pubmed: 31256470
Ann Intern Med. 2013 Feb 5;158(3):200-7
pubmed: 23295957
Ann Fam Med. 2010 Jul-Aug;8(4):348-53
pubmed: 20644190
Biol Psychiatry. 2013 Apr 1;73(7):679-82
pubmed: 23237317
J Clin Transl Sci. 2020 Apr 03;4(4):345-353
pubmed: 33244416
J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Lancet Psychiatry. 2021 Mar;8(3):202-214
pubmed: 33571453
Qual Life Res. 1999 May;8(3):209-24
pubmed: 10472152
Aust N Z J Psychiatry. 2000 Dec;34(6):997-1008
pubmed: 11127632
PLoS One. 2022 May 25;17(5):e0268948
pubmed: 35613149
PLoS Med. 2013 Nov;10(11):e1001547
pubmed: 24223526
J Affect Disord. 2016 Oct;203:382-395
pubmed: 27371907
Lancet. 2018 Nov 10;392(10159):1789-1858
pubmed: 30496104
Br J Gen Pract. 2021 Jan 28;71(703):e85-e94
pubmed: 33431380
J Psychiatr Pract. 2006 Mar;12(2):71-9
pubmed: 16728903
Int Clin Psychopharmacol. 2010 Jul;25(4):189-98
pubmed: 20531012
Am J Psychiatry. 2006 Nov;163(11):1905-17
pubmed: 17074942
Gen Hosp Psychiatry. 2010 Jul-Aug;32(4):377-9
pubmed: 20633741
Aust J Gen Pract. 2021 Dec;50(12):954-956
pubmed: 34845476
J Gen Intern Med. 2001 Sep;16(9):606-13
pubmed: 11556941
BMC Prim Care. 2022 Sep 16;23(1):236
pubmed: 36109694
Psychiatr Serv. 2014 Aug 1;65(8):977-87
pubmed: 24789696
BMJ. 2015 May 08;350:h2147
pubmed: 25956159
Pharmacogenet Genomics. 2020 Sep;30(7):145-152
pubmed: 32433340